U.S. FDA Approves Liquidias YUTREPIA (treprostinil) Inhalation Powder forPatients with Pulmonary Arterial Hypertension (PAH) andPulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
May 23, 2025 14:28 ET | Source: Liquidia Technologies, Inc. FDA’s approval…
